Lifeboat Foundation

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhDDiscount Links: NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/Use Cod…

An exploration of the implications of immortal alien civilizations. My Patreon Page: https://www.patreon.com/johnmichaelgodierMy Event Horizon Channel: https://…

The notion of time travel has fascinated humans for thousands of years, but it’s always been a work of fiction – until now.

Scientists have discovered evidence of time travel for real, albeit at a microscopic level. Till Bohmer and Thomas Blochowicz are the lead authors of a new study, Time reversibility during the ageing of materials, which is published in Nature Physics.

The research from the two researchers at the Technical University of Darmstadt in Germany focuses on time effectively ‘shuffling’ in the structure of certain materials like glass.

“Aging reversal is something that’s been proven about eight different ways in animals,” geneticist George Church says. So when will humans get to turn back t…

A new tool that uses images of your face, tongue, and retina, could help gauge your risk of developing chronic diseases.

A new study claims that low-frequency ultrasound can reverse aspects of replicative and chemically induced senescence in vitro [1].

The age-related increase in senescent cell burden is thought to contribute to many processes of aging. Most of the attempts to deal with it involve senolytics: drugs that eliminate senescent cells.

However, it may be possible to re-educate them instead. Senomorphics are compounds that change senescent cells in a way that renders them benign, but they are much less common. The authors of this new pre-print study (it has not yet been peer-reviewed) claim to have found an even more impressive way to solve the senescent cell problem: by rejuvenating them with ultrasound.

Cells in the human body contain power-generating mitochondria, each with their own mtDNA—a unique set of genetic instructions entirely separate from the cell’s nuclear DNA that mitochondria use to create life-giving energy. When mtDNA remains where it belongs (inside of mitochondria), it sustains both mitochondrial and cellular health—but when it goes where it doesn’t belong, it can initiate an immune response that promotes inflammation.

Now, Salk scientists and collaborators at UC San Diego have discovered a novel mechanism used to remove improperly functioning mtDNA from inside to outside the mitochondria. When this happens, the mtDNA gets flagged as foreign DNA and activates a cellular pathway normally used to promote inflammation to rid the cell of pathogens, like viruses.

The findings, published in Nature Cell Biology, offer many new targets for therapeutics to disrupt the inflammatory pathway and therefore mitigate inflammation during aging and diseases, like lupus or rheumatoid arthritis.

Histopathology describes the process of examining pieces of tissue using a microscope. Light microscopic (LM) examination of tissue helps diagnose several types of cancer by allowing pathologists to view cellular changes within a biopsy sample.

The workload of pathologists has increased in recent years due to policies that encourage screening for early cancer diagnoses. In addition, longer life expectancies and scientific advances have led to an increased number of cancer survivors, further increasing the need for pathology evaluations. Thus, strategies to efficiently utilize the limited pathology resources have become essential to maintaining standards of care and the health and safety of patients.

Digital pathology (DP) has emerged as an alternative method for analyzing tissue samples by stitching together digital images from histopathology slides. Automated slide scanners can rapidly generate these high-resolution images with minimal human interaction. In addition to the speed, DP does not require a microscope, offering remote viewing possibilities. Pathologists and other healthcare professionals can easily share images.

— Anti-aging vaccine shows promise in mice — will it work in humans?

“This research is still in the early stages and may be a number of years from being available to patients,” Dr. David Pinato, a clinician scientist at Imperial College London’s Department of Surgery & Cancer and a consultant medical oncologist at Imperial College Healthcare NHS Trust, said in the statement. “But this trial is laying crucial groundwork that is moving us closer towards new therapies that are potentially less toxic and more precise.”

The first person treated in the U.K. arm of the trial wishes to remain anonymous, but said “I was pleased to be offered a chance to take part in a new trial.”